Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [10/07/2025 16:11 PDT] ANIX SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [10/07/2025 16:11 PDT] Anixa Biosciences, Inc. (NASDAQ:ANIX), Up By 100% ($3.6) From $3.6 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [09/19/2025 07:01 PDT] ANIX Expected to Trade Down After Bearish Patterns Develop
• [09/17/2025 07:17 PDT] ANIX Expected to Trade Up After Bullish Patterns Develop
• [08/18/2025 07:13 PDT] ANIX Expected to Trade Down After Bearish Patterns Develop